Aby wyświetlić tę treść, wymagana jest subskrypcja JoVE. Zaloguj się lub rozpocznij bezpłatny okres próbny.
Pulmonary arterial hypertension (PAH) is a disease of pulmonary arterioles that leads to their obliteration and the development of right ventricular failure. Rodent models of PAH are critical in understanding the pathophysiology of PAH. Here we demonstrate hemodynamic characterization, with right heart catheterization and echocardiography, in the mouse and rat.
Pulmonary arterial hypertension (PAH) is a rare disease of the pulmonary vasculature characterized by endothelial cell apoptosis, smooth muscle proliferation and obliteration of pulmonary arterioles. This in turn results in right ventricular (RV) failure, with significant morbidity and mortality. Rodent models of PAH, in the mouse and the rat, are important for understanding the pathophysiology underlying this rare disease. Notably, different models of PAH may be associated with different degrees of pulmonary hypertension, RV hypertrophy and RV failure. Therefore, a complete hemodynamic characterization of mice and rats with PAH is critical in determining the effects of drugs or genetic modifications on the disease.
Here we demonstrate standard procedures for assessment of right ventricular function and hemodynamics in both rat and mouse PAH models. Echocardiography is useful in determining RV function in rats, although obtaining standard views of the right ventricle is challenging in the awake mouse. Access for right heart catheterization is obtained by the internal jugular vein in closed-chest mice and rats. Pressures can be measured using polyethylene tubing with a fluid pressure transducer or a miniature micromanometer pressure catheter. Pressure-volume loop analysis can be performed in the open chest. After obtaining hemodynamics, the rodent is euthanized. The heart can be dissected to separate the RV free wall from the left ventricle (LV) and septum, allowing an assessment of RV hypertrophy using the Fulton index (RV/(LV+S)). Then samples can be harvested from the heart, lungs and other tissues as needed.
Pulmonary arterial hypertension (PAH) is a disease of the pulmonary vasculature associated with inflammatory cell infiltration, smooth muscle proliferation and endothelial cell apoptosis. These changes result in obliteration of pulmonary arterioles, subsequently leading to right ventricular (RV) dysfunction and heart failure. In order to understand the pathophysiology underlying PAH and RV failure in PAH, a number of different models, including genetic and pharmacologic models, for studying this disease have been developed (reviewed elsewhere1,2).
Of these models, the most popular are hypoxia-induced (Hx) PAH in the mouse and the monocrotaline (MCT) and SU5416-hypoxia (SuHx) models in the rat. In the mouse Hx model, mice are exposed to 4 weeks of hypoxia (either normobaric or hypobaric, corresponding to an altitude of 18,000 feet with a FiO2 of 0.10), with the resultant development of medial proliferation, increased RV systolic pressures and the development of RV hypertrophy3. MCT at a single dose of 60 mg/kg results in injury to pulmonary endothelial cells through an unclear mechanism that then results in the development of PAH4. SU5416 is a an inhibitor of the vascular endothelial growth factor receptors (VEGFR) 1 and 2 blocker, and treatment with a single subcutaneous injection of 60 mg/kg followed by exposure to chronic hypoxia for 3 weeks results in permanent pulmonary hypertension with pathologic changes similar to that seen in the human disease, with the formation of obliterative vascular lesions5. In the past years, several transgenic mouse models for pulmonary hypertension have been developed. These include knockout and mutations of the bone morphogenetic protein receptor 2 (BMPR2), as BMPR2 gene mutations are found in both familial and idiopathic forms of PAH, heme oxygenase-1 knockout and IL-6 overexpression (reviewed elsewhere1,2).
These different rodent models of PH have different levels of pulmonary hypertension, RV hypertrophy and RV failure. While the hypoxia and various transgenic mouse models result in much milder PAH than the either rat model1, it does allow testing of different genetic mutations and their associated molecular signaling pathways. The MCT model does result in severe PAH, although MCT appears to be toxic to endothelial cells in multiple tissues4. The SuHx model is characterized by vascular changes more similar to that seen in idiopathic PAH in humans, although requires both pharmacologic manipulation and hypoxia exposure. Moreover, in all of these models, there may be a disconnection between the histopathologic changes, pulmonary pressures and RV function associated with the development of PAH. This is in contrast to the human disease, where there is usually a proportionate relationship between histopathologic changes, the severity of pulmonary hypertension and the degree of RV failure. Thus, a comprehensive characterization of these rodent models of PH is required, and involves assessments of RV function (typically by echocardiography), hemodynamics (by cardiac catheterization) and histopathology of the heart and lungs (from tissue harvesting).
In this protocol, we describe the basic techniques used for hemodynamic characterization of PAH models in the rat and the mouse. These general techniques can be applied to any study of the right ventricle and pulmonary vasculature and is not limited to models of PAH. Visualizing the RV by echocardiography is relatively straightforward in rats, but is more challenging in mice due to their size and the complex geometry of the RV. Moreover, some surrogates used for quantifying RV function, such as TAPSE, pulmonary artery (PA) acceleration time and PA Doppler waveform notching, are not well validated in humans and correlate only weakly with assessment of pulmonary hypertension and RV function by invasive hemodynamics. Determination of the RV hemodynamics is best done with a closed-chest, to maintain the effects of a negative intrathoracic pressure with inspiration, although open chest catheterization with an impedance catheter allows determination of pressure-volume (PV) loops and a more detailed hemodynamic characterization. As with any procedure, developing experience with the procedures is critical to experimental success.
All procedures described follow the animal care guidelines of Duke University School of Medicine.
1. Prior to Starting the Procedure
Note: Prior to any animal procedures, ensure that appropriate institutional permission has been obtained. As with all procedures, use appropriate pain medication to ensure that there is no animal suffering.
2. Echocardiography
Note: A full description of rodent echocardiography is described elsewhere7. For the mouse, prior to anesthesia, images can be obtained on the awake, manually restrained animal. For the rat, anesthesia prior to echocardiography is preferred as rats are too large to be manually restrained while awake).
3. Right Heart Catheterization
4. Collection of Heart and Lung Samples
Note: As the procedures here are described as terminal, the animal must be euthanized after either closed- or open-chest right heart catheterization.
As right heart catheterization in rodents is typically a terminal procedure that is not applicable to longitudinal follow-up, echocardiography is an excellent noninvasive alternative for screening and follow-up12. While pulmonary artery systolic pressure in human PAH on echocardiography is usually derived from tricuspid regurgitation that is usually straightforward to be obtained in the apical view, such a view is not reliably obtained in rodents, preventing the estimation of pulmonary artery systolic pressure...
The protocols outlined here describe a comprehensive characterization of hemodynamics and right ventricular function in rodent models of pulmonary hypertension. While right heart catheterization as described here is a terminal procedure, the mortality associated with echocardiography is minimal, which allows for screening and follow-up of disease progression. However, similar to patients with PH having markedly increased mortality with anesthesia17, in our experience, rats with severe PH do not tolerate anesth...
The authors have nothing to disclose.
SR is supported by NIH K08HL114643, Gilead Research Scholars in Pulmonary Arterial Hypertension and a Burroughs Wellcome Fund Career Award for Medical Scientists.
Name | Company | Catalog Number | Comments |
Vevo 2100 Imaging System (120V) | VisualSonics, inc. | VS-11945 | |
Vevo 2100 Imaging Station | VisualSonics, inc. | ||
High-frequency Mechanical Transducers | VisualSonics, inc. | MS250, MS550D, MS400 | |
Ultrasound Gel Parker | Laboratories Inc. | 01-08 | |
PowerLab 4/35 | ADInstruments | ML765 | |
Labchart 8 | ADInstruments | ||
BP transducer with stopcock and cable | ADInstruments | MLT1199 | |
BP transducer calibration kit | ADInstruments | MLA1052 | |
Mikro-Tip Pressure Catheter for mouse | Millar | SPR-1000 | Alternative catheter available from Scisense FT111B (mouse) and FT211B (rat) |
Mikro-Tip Pressure Catheter for rat | Millar | SPR-513 | Alternative catheter available from Scisense FT111B (mouse) and FT211B (rat) |
Millar Mikro-Tip ultra-miniature PV loop catheter for mice | Millar | PVR-1035 | Alternative catheter available from Scisense FT112 (mouse) |
Millar Mikro-Tip ultra miniature PV loop catheter for rats | Millar | SPR-869 | Alternative catheter available from Scisense FT112 (mouse) |
Millar PV system MPVS-300 | Millar | MPVS-300 | |
4-0 Silk Black Braid 100 Yard Spool | Roboz Surgical | SUT-15-2 | |
6-0 Silk Black Braid 100 Yard Spool | Roboz Surgical | SUT-14-1 | |
Iris Scissors, Delicate, Integra Miltex | VWR | 21909-248 | |
VWR Dissecting Scissors, Sharp/Blunt Tip | VWR | 82027-588 | |
VWR Delicate Scissors, 4 1/2" | VWR | 82027-582 | |
Two star Hemostats, Excelta | VWR | 63042-090 | |
Neutral-buffered formalin | VWR | 89370-094 | |
Crotaline | Sigma | C2401 | |
SU5416 | Tocris Biosciences | 3037 | |
3.5X-45X Boom Stand Trinocular Zoom Stereo Microscope | AmScope | SM-3BX | |
PE (Polyethylene Tubing)-10 | Braintree Scientific Inc | PE10 36 FT | |
PE (Polyethylene Tubing)-50 | Braintree Scientific Inc | PE50 36 FT | |
PE (Polyethylene Tubing)-60 | Braintree Scientific Inc | PE60 36 FT | |
Tabletop Isoflurane Anesthesia Unit | Kent Scientific | ACV-1205S | |
Surgisuite multi-functional surgical platform | Kent Scientific | Surgisuite | |
Retractor set | Kent Scientific | SURGI-5002 | |
Anesthesia induction chamber | VetEquip | 941443 | |
Anesthesia Gas filter canister | Kent Scientific | ACV-2001 | |
Rodent nose cone | VetEquip | 921431 |
Zapytaj o uprawnienia na użycie tekstu lub obrazów z tego artykułu JoVE
Zapytaj o uprawnieniaPrzeglądaj więcej artyków
This article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. Wszelkie prawa zastrzeżone